Richter-Helm BioLogics

Strides Pharma Science Limited is shifting focus to chronic therapies from acute as it seeks to weed out excessive seasonality in its US business and move towards a US revenue target of $400-500m tha

Hungarian player Gedeon Richter has struck agreements worth more than €100m ($109m) to buy out a couple of joint ventures from its long-term German partner Helm, including a JV ( Richter-Helm BioLog